Yan Zhi Tan

Yan Zhi Tan

Auto-generated profile, based on publicly available information

Yan Zhi Tan

Department of Pharmacy, Singapore General Hospital, Singapore

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2019 in International Journal Of Clinical Practice
Verified
Journal Article
Closed access
PDF file
MCMcVin Hua Heng Cheen
McVin Hua Heng Cheen
YTYan Zhi Tan
Yan Zhi Tan
LOLing Fen Oh
Ling Fen Oh
HWHwee Lin Wee
Hwee Lin Wee
JTJulian Thumboo
Julian Thumboo

30 January 2019 in Intestinal Research
Verified
Journal Article
Open access
PDF file
PHPrisca Yue Min Ho
Prisca Yue Min Ho
WHWenjia Hu
Wenjia Hu
YLYing Yun Lee
Ying Yun Lee
CGChuxi Gao
Chuxi Gao
YTYan Zhi Tan
Yan Zhi Tan
WOWan Chee Ong
Wan Chee Ong
Inflammatory bowel disease (IBD) is associated with considerable impairment of patients' health-related quality of life (HRQoL). Knowledge of factors that significantly affect IBD patients' HRQoL can contribute to better patient care. However, the HRQoL of IBD patients in non-Western countries are limited. Hence, we assessed the HRQoL of Singaporean IBD patients and identified its determinants. A prospective, cross-sectional study was conducted at Singapore General Hospital outpatient IBD Centre. The HRQoL of IBD patients was assessed using the short IBD questionnaire (SIBDQ), Short Form-36 physical and mental component summary (SF-36 PCS/MCS) and EuroQol 5-dimensions 3-levels (EQ-5D-3L) and visual analogue scale (VAS). Independent samples t-test was used to compare HRQoL between Crohn's disease (CD) and ulcerative colitis (UC). Determinants of HRQoL were identified through multiple linear regression. A total of 195 IBD patients (103 UC, 92 CD) with a mean disease duration of 11.2 years were included. There was no significant difference in HRQoL between patients with UC and CD. Factors that significantly worsened HRQoL were presence of active disease (b=-6.293 [SIBDQ], -9.409 [PCS], -9.743 [MCS], -7.254 [VAS]), corticosteroids use (b=-7.392 [SIBDQ], -10.390 [PCS], -8.827 [MCS]), poor medication adherence (b=-4.049 [SIBDQ], -1.320 [MCS], -8.961 [VAS]), presence of extraintestinal manifestations (b=-13.381 [PCS]), comorbidities (b=-4.531 [PCS]), non-employment (b=-9.738 [MCS], -0.104 [EQ-5D-3L]) and public housing (b=-8.070 [PCS], -9.207 [VAS]). The HRQoL is impaired in this Asian cohort of IBD. The magnitude of HRQoL impairment was similar in UC and CD. Clinical characteristics were better determinants of patients' HRQoL than socio-demographic factors. Recognizing the factors that impact patients' HRQoL would improve the holistic management of IBD patients.

1 January 2022 in Journal of the American Pharmacists Association
Verified
Journal Article
Closed access
JCJin Jian Chong
Jin Jian Chong
YTYan Zhi Tan
Yan Zhi Tan
LCLita Sui Tjien Chew
Lita Sui Tjien Chew
KTKok Hian Tan
Kok Hian Tan
AWAiwen Wang
Aiwen Wang

20 November 2019 in Current Diabetes Reports
Verified
Journal Article
Closed access
PDF file
YCYu Ting Chen
Yu Ting Chen
YTYan Zhi Tan
Yan Zhi Tan
MCMcvin Cheen
Mcvin Cheen
HWHwee Lin Wee
Hwee Lin Wee

16 December 2018 in Journal of Diabetes
Verified
Journal Article
Closed access
PDF file
YTYan Zhi Tan
Yan Zhi Tan
MCMcVin Hua Heng Cheen
McVin Hua Heng Cheen
SGSu‐Yen Goh
Su‐Yen Goh
YBYong Mong Bee
Yong Mong Bee
PLPaik Shia Lim
Paik Shia Lim
JTJulian Thumboo
Julian Thumboo

1 April 2024 in Vasa
Verified
Journal Article
Open access
MLMichael Lichtenberg
Michael Lichtenberg
JMJihad Mustapha
Jihad Mustapha
YTYan Zhi Tan
Yan Zhi Tan
KSKonstantinos Stavroulakis
Konstantinos Stavroulakis
CMCatherina Meijer
Catherina Meijer
HBHenri Vanden Bavière
Henri Vanden Bavière
Summary: Background: Intravascular ultrasound (IVUS)-guided percutaneous transluminal angioplasty (PTA) might offer clinical benefits compared to angiography-guided PTA in patients with peripheral artery disease (PAD). A cost-effectiveness model was developed to examine the benefits and costs of IVUS-guided PTA versus angiography-guided PTA in PAD patients with femoropopliteal (FP) occlusive disease. Methods: A two-step model (a one-year decision tree followed by a lifetime semi-Markov model) was developed from a German healthcare payer perspective to estimate the costs and outcomes over a one-year and lifetime horizon. Clinical events included target lesion revascularization (TLR), amputation, and death. Transition probabilities and utility values were derived from published literature. Healthcare costs were based on German Diagnosis Related Groups (DRG) codes. Costs and outcomes were discounted at a rate of 3% per year. The incremental cost-effectiveness ratio (ICER) was calculated, and sensitivity analyses were performed to assess the robustness of the results. Results: In the one-year horizon, IVUS-guided PTA resulted in incremental quality-adjusted life-years (QALY) and costs of 0.02 and €919 per patient respectively, with a corresponding ICER of €45,195/QALY gained versus angiography-guided PTA. In the lifetime horizon, IVUS-guided PTA outperforms angiography-guided PTA; it was associated with a cost saving of €46 per patient and incremental QALY of 0.22. Utility value for post-TLR, as well as probabilities of death and TLR had the greatest impact on the one-year ICER, while cost of TLR and probabilities of TLR and amputation influenced the lifetime ICER most. The probability of IVUS-guided PTA being cost-effective at a willingness-to-pay (WTP) threshold of €50,000/QALY was 50.4% in the one-year horizon and increased to 85.9% in the lifetime horizon. Conclusions: In this analysis IVUS-guided PTA among patients with symptomatic FP atherosclerosis was cost-saving in a lifetime horizon from the German healthcare payer perspective.